International Journal of

Molecular Sciences

Editorial
Breast Cancer: From Pathophysiology to Novel Therapeutic
Approaches 2.0
Antonella Zannetti

Institute of Biostructures and Bioimaging, National Research Council (IBB-CNR), 80145 Naples, Italy;
antonella.zannetti@cnr.it

Breast cancer (BC) is the most common malignancy in women worldwide. It is a

very heterogeneous disease characterized by different molecular profiles that are clinically
divided into three main subtypes by hormone receptor (ER and PR) and HER2 (ERBB2)
status: luminal ER-positive and PR-positive, which is further subdivided into luminal
A and B, HER2-positive, and triple-negative breast cancer (TNBC) [1]. To date, in the
fight against breast cancer, the screening program is the most important aid in reducing
mortality caused by this disease. Conventional chemo- and radiotherapy, often including
targeted agents, represent the main systemic treatment used for BC patients, although
many develop drug resistance, relapse, and secondary metastases [1]. The early stage of
BC is considered curable in 70–80% of patients due to improved multimodal therapy, while
advanced metastatic BC is an unmet challenge. Many studies are ongoing, and efforts are
being made to identify new molecular biomarkers to improve diagnostic and therapeutic
approaches. Therefore, the aim of this Special Issue is to highlight the current preclinical
and clinical studies conducted in breast cancer research to shed light on the deep molecular
signatures and the next therapeutic scenario of this highly heterogeneous disease.
All of the articles published in “Breast Cancer: From Pathophysiology to Novel
Therapeutic Approaches 2.0” meet these criteria and report interesting results, often using
transcriptomic approaches, on the identification and implication of novel biomarkers that
are able to discriminate between different types of BC and between responder and non-
responder patients. In addition, new possible prognostic factors related to overall survival
have been investigated, but most importantly, new targeted and less toxic therapies have
Citation: Zannetti, A. Breast Cancer:
been evaluated for use alone or in combination with chemotherapeutic agents.
From Pathophysiology to Novel
In an interesting review, Chiodo et colleagues [2] clarified the contribution of steroid
Therapeutic Approaches 2.0. Int. J.
hormones and their receptors in the growth, development, and lifetime changes of the
Mol. Sci. 2023, 24, 2542.
mammary gland as well as its crucial role in breast cancer development and progression.
https://doi.org/10.3390/
They elucidated the controversial impact of androgens/AR in preventing or promoting
ijms24032542
breast cancer and the signaling pathways involved.
Received: 5 December 2022 It is noteworthy that by analyzing the TCGA/GTEx datasets available within GEPIA2
Revised: 23 December 2022 and using the tissue microarray of a cohort of 252 samples, a study showed that breast
Accepted: 13 January 2023 cancer patients with higher methionine adenosyltransferases 2 (MAT2A) and no MAT1A
Published: 29 January 2023
had a worse survival rate (p = 0.0057). The authors found that a higher cytoplasmic/nuclear
(C/N) MAT2A protein expression ratio correlated with poor overall survival, and a MAT2A
C/N expression ratio ≥ 1.0 was determined as an independent risk factor by Cox regression
analysis [3].
Copyright: © 2023 by the author.
Licensee MDPI, Basel, Switzerland.
del Mar Noblejas-López et al. [4] demonstrated, using the transcriptomic mapping
This article is an open access article
of cyclin-dependent kinases (CDKs), that the expression of CDK9 predicted a detrimental
distributed under the terms and outcome in basal-like breast cancer and, particularly, in the luminal B subtype with HER2+
conditions of the Creative Commons expression. They found that a novel proteolysis targeting chimera (PROTAC) compound
Attribution (CC BY) license (https:// against CDK9, THAL-SNS-032, showed a major anti-tumoral effect on breast cancer cell
creativecommons.org/licenses/by/ lines, expressing both ER and HER2, such as BT474. Interestingly, drug-resistant cells
4.0/). derived from BT474 cell line with resistance to trastuzumab (BT474-RH), to the antibody

Int. J. Mol. Sci. 2023, 24, 2542. https://doi.org/10.3390/ijms24032542 https://www.mdpi.com/journal/ijms

Int. J. Mol. Sci. 2023, 24, 2542 2 of 3

drug conjugate TDM1 (BT474-TDM1R), or to the kinase inhibitor lapatinib (BT474-LAPA-R)

displayed a particular sensitivity to THALSNS-032. Conversely, low doses of the com-
pound induced severe toxicity in BT474 xenografts, in particular in in the gastrointestinal
epithelium, without causing a significant reduction of tumor volume, thus showing its
inverse therapeutic index.
A synergic antitumoral effect of Ruxolitinib (an oral selective inhibitor of Janus kinases
1 and 2) and Calcitriol in HER2-enriched and triple negative subtypes of breast cancer
cells was reported by Schneider and colleagues [5]. The combined treatment caused cell
proliferation inhibition, apoptosis induction, cell cycle arrest, and the alteration of the cell
signaling protein expression underlying these mechanisms. Similar results were obtained
in vivo with Ruxolitinib and Calcitriol that showed a synergistic inhibitory effect on tumor
growth in MDA-MB-468 xenografts, corroborating the in vitro observations on the potential
of this treatment in certain subtypes of breast cancer.
To improve the selectivity and bioavailability of chemotherapeutic agents, such as
the platinum complexes class and overcome multiple mechanisms of drug resistance,
Czarnomysy et al. [6] synthesized a novel imidazole platinum(II) complex conjugated
with the second-generation polyamidoamine (PAMAM) dendrimer (PtMet2–PAMAM).
They showed that this compound increased apoptosis via caspase-9 (intrinsic pathway)
and caspase-8 (extrinsic pathway) as well as triggered autophagy through p38 pathway
activation in different breast cancer cells. Furthermore, the complex inhibited drug efflux
transporters and its positive charge increased the tumor cell uptake, demonstrating the
ability of PtMet2–PAMAM to reverse multidrug resistance [6].
TNBC represents one of the most aggressive types of BC because of its high hetero-
geneity and plasticity [7]. Currently, chemotherapy still remains the main therapeutic
option, including taxane- and anthracycline-based treatments for TNBC, despite the high
rate of non-responders due to the occurrence of drug resistance. Interestingly, a study by
Gangapuram et al. [8] compared the transcriptome profile of TNBC cells in response a
novel cytostatic compound, a tetrahydroisoquinoline named GM-4-53, and paclitaxel. Both
treatments caused, in TNBC cells, changes in transcripts that influence microtubule spindle
formation, chromosome segregation, mitosis/cell cycle, and transforming growth factor
(TGF) signaling as well as the downregulation of “inhibitor of DNA Binding/Inhibitor
of differentiation” (ID) transcripts, amphiregulin (AREG) and epiregulin (EREG), with
GM-4-53 having more significant effects than paclitaxel. The authors hypothesize that
given the efficient solubility of GM-4-53, its low molecular weight (MW; 296) and its abil-
ity to penetrate a small solid tumor mass and effectively block the cell cycle, this drug
may have future therapeutic value in treating TNBC. The effect of desethylamiodarone
(DEA), the major metabolite of amiodarone (AM), as anti-tumoral agent was investigated
by Gallyas and colleagues [9] in TNBC cells. They found that DEA reduced tumor cell
viability, proliferation, and invasion; lowered mitochondrial transmembrane potential; and
induced mitochondrial fragmentation. In addition, DEA-resistant TNBC cells showed an
upregulation of cyclooxygenase 2 (COX-2) and its activity was counteracted by the specific
inhibitor celecoxib.
Several innovative approaches are being explored to overcome limitations due to
the lack of well-defined TNBC biomarkers. Recently, Camorani et al., using a TNBC cell-
SELEX approach, generated a panel of six RNA aptamers able to bind at high efficiency
to the surface proteins of human TNBC cells without recognizing non-malignant cells or
non-TNBC breast cancer cells [10]. Aptamers recognize their targets with high affinity
and specificity in a manner similar to antibody–antigen interactions and have been used
to specifically deliver through nanovector-based chemotherapeutic agents and immune
checkpoint inhibitors in TNBC cells [11,12]. In a study published in this Special Issue,
Camorani et colleagues [13] optimized three of six aptamers by shortening and proved that
the truncated aptamers showed superb nuclease resistance, specific binding to TNBC target
cells, and rapid internalization into acidic compartments and also hampered the growth of
TNBC cells as mammospheres.
Int. J. Mol. Sci. 2023, 24, 2542 3 of 3

In conclusion, taken together, the studies published in this Special Issue demonstrate
that the future of research in BC, through the deeper knowledge of molecular mechanisms
associated with drug resistance and underlying tumor progression, is reaching the point
where treatments can be tailored to each individual patient.

Conflicts of Interest: The author declares no conflict of interest.

References
1. Loibl, S.; Poortmans, P.; Morrow, M.; Denkert, C.; Curigliano, G. Breast cancer. Lancet 2021, 397, 1750. [CrossRef] [PubMed]
2. Chiodo, C.; Morelli, C.; Cavaliere, F.; Sisci, D.; Lanzino, M. The Other Side of the Coin: May Androgens Have a Role in Breast
Cancer Risk? Int. J. Mol. Sci. 2021, 23, 424. [CrossRef] [PubMed]
3. Chu, P.Y.; Wu, H.J.; Wang, S.M.; Chen, P.M.; Tang, F.Y.; Chiang, E.I. MAT2A Localization and Its Independently Prognostic
Relevance in Breast Cancer Patients. Int. J. Mol. Sci. 2021, 22, 5382. [CrossRef] [PubMed]
4. Noblejas-López, M.D.M.; Gandullo-Sánchez, L.; Galán-Moya, E.M.; López-Rosa, R.; Tébar-García, D.; Nieto-Jiménez, C.; Gómez-
Juárez, M.; Burgos, M.; Pandiella, A.; Ocaña, A. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast
Cancer. Int. J. Mol. Sci. 2022, 23, 5476. [CrossRef] [PubMed]
5. Schneider, J.; Jeon, Y.W.; Suh, Y.J.; Lim, S.T. Effects of Ruxolitinib and Calcitriol Combination Treatment on Various Molecular
Subtypes of Breast Cancer. Int. J. Mol. Sci. 2022, 23, 2535. [CrossRef] [PubMed]
6. Czarnomysy, R.; Muszyńska, A.; Rok, J.; Rzepka, Z.; Bielawski, K. Mechanism of Anticancer Action of Novel Imidazole
Platinum(II) Complex Conjugated with G2 PAMAM-OH Dendrimer in Breast Cancer Cells. Int. J. Mol. Sci. 2021, 22, 5581.
[CrossRef] [PubMed]
7. Sarnella, A.; D’Avino, G.; Hill, B.S.; Alterio, V.; Winum, J.Y.; Supuran, C.T.; De Simone, G.; Zannetti, A. A Novel Inhibitor of
Carbonic Anhydrases Prevents Hypoxia-Induced TNBC Cell Plasticity. Int. J. Mol. Sci. 2020, 21, 8405. [CrossRef] [PubMed]
8. Gangapuram, M.; Mazzio, E.A.; Redda, K.K.; Soliman, K.F.A. Transcriptome Profile Analysis of Triple-Negative Breast Cancer
Cells in Response to a Novel Cytostatic Tetrahydroisoquinoline Compared to Paclitaxel. Int. J. Mol. Sci. 2021, 22, 7694. [CrossRef]
[PubMed]
9. Gallyas, F., Jr.; Ramadan, F.H.J.; Andreidesz, K.; Hocsak, E.; Szabo, A.; Tapodi, A.; Kiss, G.N.; Fekete, K.; Bognar, R.;
Szanto, A.; et al. Involvement of Mitochondrial Mechanisms and Cyclooxygenase-2 Activation in the Effect of Desethylamio-
darone on 4T1 Triple-Negative Breast Cancer Line. Int. J. Mol. Sci. 2022, 23, 1544. [CrossRef] [PubMed]
10. Camorani, S.; Granata, I.; Collina, F.; Leonetti, F.; Cantile, M.; Botti, G.; Fedele, M.; Guarracino, M.R.; Cerchia, L. Novel Aptamers
Selected on Living Cells for Specific Recognition of Triple-Negative Breast Cancer. iScience 2020, 23, 100979. [CrossRef] [PubMed]
11. Agnello, L.; Tortorella, S.; d’Argenio, A.; Carbone, C.; Camorani, S.; Locatelli, E.; Auletta, L.; Sorrentino, D.; Fedele, M.;
Zannetti, A.; et al. Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated
polymeric nanovectors. J. Exp. Clin. Cancer Res. 2021, 40, 239. [CrossRef] [PubMed]
12. Camorani, S.; Tortorella, S.; Agnello, L.; Spanu, C.; d’Argenio, A.; Nilo, R.; Zannetti, A.; Locatelli, E.; Fedele, M.;
Franchini, M.C.; et al. Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silenc-
ing in Triple-Negative Breast Cancer Cells. Pharmaceutics 2022, 14, 2225. [CrossRef] [PubMed]
13. Camorani, S.; d’Argenio, A.; Agnello, L.; Nilo, R.; Zannetti, A.; Ibarra, L.E.; Fedele, M.; Cerchia, L. Optimization of Short RNA
Aptamers for TNBC Cell Targeting. Int. J. Mol. Sci. 2022, 23, 3511. [CrossRef] [PubMed]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual
author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to
people or property resulting from any ideas, methods, instructions or products referred to in the content.